Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01547546 · ClinicalTrials.gov registry record · Phase 1
A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma
A Phase 1 study of Glioblastoma, Glioma, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
- 5
- Study locations
NCT01547546: Completed Phase 1 study of Glioblastoma, Glioma, sponsored by Genentech.
NCT01547546 is a Phase 1 study of Glioblastoma, Glioma that has completed, run by Genentech. The registered enrollment target is 29 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (52% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01547546, a Phase 1 study of Glioblastoma, Glioma, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
- 5
- Study locations
Study Summary
This open-label, multicenter, Phase I, dose-escalating study will evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics and efficacy of GDC-0084 in patients with progressive or recurrent high-grade glioma. Stage 1 is the dose escalation part of the study. Stage 2, patients will receive GDC-0084 at a recommended dose for future studies.
Conditions Studied
Interventions
- DRUG GDC-0084
Study Locations (5)
Massachusetts
- - Boston
- - Boston
California
- - Los Angeles
Texas
- - Houston
Barcelona
- - Barcelona
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2012-04 |
| Est. Completion | 2015-01 |
| Phase | Phase 1 |
What the finished NCT01547546 record still lists
NCT01547546 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (52% lower).
The record links to 1 condition, with Glioblastoma, Glioma appearing as the primary indexed condition, and to 1 intervention - of which GDC-0084 is the first listed.
NCT01547546 lists 5 locations in 4 states (Massachusetts, California, Texas).
Frequently Asked Questions
What is clinical trial NCT01547546 about?
NCT01547546 is a clinical study titled "A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma". This open-label, multicenter, Phase I, dose-escalating study will evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics and efficacy of GDC-0084 in patients with progressive or recurrent high-grade glioma. Stage 1 is the dose escalation part of the study. Stage 2, patients will re...
What is the current status of trial NCT01547546?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2012-04. Estimated completion is 2015-01.
What conditions does trial NCT01547546 study?
This clinical trial studies the following conditions: Glioblastoma, Glioma.
What interventions are being tested in trial NCT01547546?
The interventions under investigation include: GDC-0084 (DRUG).
Who is sponsoring clinical trial NCT01547546?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01547546 being conducted?
This trial has 5 study locations across California, Massachusetts, Texas, Barcelona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01547546's enrollment target sits among peer trials
29 1440th of 2000 higher than 554 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia